Equities Analysts Offer Predictions for Kamada Q4 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for Kamada in a research report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.05 per share for the quarter, down from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.26 per share. HC Wainwright also issued estimates for Kamada’s FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $42.47 million for the quarter, compared to analysts’ expectations of $39.70 million. Kamada had a net margin of 9.92% and a return on equity of 6.36%.

Separately, StockNews.com downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Kamada Stock Performance

NASDAQ:KMDA opened at $5.81 on Friday. Kamada has a 52-week low of $4.60 and a 52-week high of $6.53. The stock has a fifty day moving average of $5.48 and a 200 day moving average of $5.47. The firm has a market capitalization of $333.96 million, a price-to-earnings ratio of 20.75 and a beta of 1.05.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Kamada in the 3rd quarter worth about $77,000. Plato Investment Management Ltd purchased a new stake in Kamada in the third quarter worth approximately $117,000. Vanguard Group Inc. grew its position in Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after acquiring an additional 100,800 shares during the last quarter. Finally, Y.D. More Investments Ltd raised its stake in shares of Kamada by 1,956.0% during the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after acquiring an additional 690,842 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.